Finance

Beta
Lists
SLN:NASDAQ
Silence Therapeutics PLC - ADR
$10.79
+6.41%
(+0.65) 1D
$10.60
-1.76% (-0.19)
After hours
Closed: Jun 29, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SLN...
Open
$10.43
High
$10.99
Low
$9.96
Mkt. cap
509.66M
Avg. vol.
373.62K
Volume
12.00
52-wk high
$10.99
52-wk low
$4.19
EPS
-$1.59
Beta
1.49
Shares outstanding
47.23M
No. of employees
88
Open
$10.43
High
$10.99
Low
$9.96
Mkt. cap
509.66M
Avg. vol.
373.62K
Volume
12.00
52-wk high
$10.99
52-wk low
$4.19
EPS
-$1.59
Beta
1.49
Shares outstanding
47.23M
No. of employees
88
News stories
From sources across the web
Profile
Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London. Wikipedia
About Silence Therapeutics PLC - ADR
CEOCraig A Tooman
Employees88
Founded1994
Headquarters-
SectorBiotechnology
Websitesilence-therapeutics.com
Analyst ratings
Based on 5 analysts giving stock ratings to SLN in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for SLN in the last 3 months.
Highest
Current $10.79
$75.00 (+595.09%)
Average
$42.33 (+292.31%)
Lowest
$25.00 (+131.70%)
Analyst
Recommendation
Action
Price target
Projected
Date
Prakhar Agrawal
Cantor Fitzgerald
Buy
Initiated
-
-
06/24/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$75.00
+595.1%
06/17/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$25.00
+131.7%
06/11/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
06/11/2026
Keay Nakae
Chardan Capital
Buy
Maintained
$27.00
+150.2%
05/07/2026
Richard Law CFA
Goldman Sachs
Sell
Maintained
$4.00
-62.9%
03/05/2026
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
224.00K
159.00K
34.00K
422.00K
Cost of goods sold
85.00K
64.00K
12.00K
11.00K
Cost of revenue
85.00K
64.00K
12.00K
11.00K
Research and development expenses
15.28M
17.96M
8.92M
8.43M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.13M
5.80M
3.73M
7.03M
Operating expense
20.41M
23.76M
12.65M
15.46M
Total operating expenses
20.49M
23.82M
12.66M
15.47M
Operating income
-20.27M
-23.66M
-12.63M
-15.05M
Other non operating income
861.00K
770.00K
865.00K
571.00K
EBT including unusual items
-27.34M
-20.96M
-11.77M
-14.96M
EBT excluding unusual items
-26.02M
-20.96M
-11.77M
-14.96M
Income tax expense
10.00K
1.00K
-
-
Effective tax rate
-0.04%
-
-
-
Other operating expenses
-
-
-
-
Net income
-27.35M
-20.96M
-11.77M
-14.96M
Net profit margin
-12,211.61%
-13,181.13%
-34,617.65%
-3,544.31%
Earnings per share
-0.55
-0.15
-0.27
-0.33
Interest and investment income
-
-
15.00K
-
Interest expense
-
-
-
-
Net interest expenses
-
-
15.00K
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.12M
-23.50M
-12.52M
-14.94M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer